Fortress生物科技 FBIO 深 沪
等待开盘 08-13 09:30:00 美东时间
2.01
+0.090
+4.69%
华盛通- 最 高2.04
- 今 开1.91
- 成交量 42.84万股
- 最 低 1.91
- 昨 收 1.92
- 总市值 5943.55万
- 52周最高 2.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.325
- 委 比 78.66%
- 总股本 2956.99万
- 历史最高 190.50
- 量 比 3.38
- 振 幅 6.77%
- 历史最低 1.325
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AstraZeneca’s Anselamimab Trial Shows Mixed Results
Fortress Biotech ( ($FBIO) ) has shared an update. On July 16, 2025, AstraZenec...
07-17 05:48
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
FibroBiologics, a clinical-stage biotech company, has completed the third $5 million tranche of a $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global, bringing total funding to $15 million. The company can seek an additional $10 million under the agreement, subject to approval. Proceeds will support research and development, including a Phase 1/2 diabetic foot ulcer clinical trial set to begin in late 2025. This co...
06-16 20:35
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
FibroBiologics, a clinical-stage biotech company with 275+ patents, appointed Jason D. Davis, CPA, as Chief Financial Officer. With over 20 years of experience in corporate finance and capital markets, Davis will support the company’s growth as it advances its Phase 1/2 trial for diabetic foot ulcers. His expertise in leading IPOs and capital raisings will be crucial for FibroBiologics’ expansion of its fibroblast-based therapeutic platform.
06-09 12:30
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress Biotech's subsidiary, Checkpoint Therapeutics, has been acquired by Sun Pharma for $4.10 per share in cash, plus a contingent value right (CVR) up to $0.70 per share. Fortress will receive ~$28 million immediately, a 2.5% royalty on UNLOXCYT™ sales, and up to $4.8 million via CVR if certain conditions are met. UNLOXCYT™, the first FDA-approved PD-L1 blocker for advanced cutaneous squamous cell carcinoma, will be commercialized globally v...
05-30 14:47
Fortress Biotech Reports Q1 2025 Financial Highlights
Fortress Biotech Inc ( ($FBIO) ) has released its Q1 earnings. Here is a breakd...
05-20 11:57
Fortress Biotech Q1 EPS $(0.48) Beats $(0.49) Estimate, Sales $13.14M Beat $11.62M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 53.85 percent increase over losses of $(1.04) per share from
05-16 04:31
Fortress Biotech Board Member Resigns for New Role
An announcement from Fortress Biotech ( ($FBIO) ) is now available. On April 15...
04-17 04:50
Fortress Biotech’s Mixed Earnings Call: Emrosi’s Launch and Challenges
Fortress Biotech Inc (($FBIO)) has held its Q4 earnings call. Read on for the m...
03-29 08:15
Fortress Biotech FY 2024 Earnings Preview
Fortress Biotech (NASDAQ:FBIO) is scheduled to announce FY earnings results on Wednesday, March 26th, after market close. The consensus EPS Estimate is -$3.28 (+61.3% Y/Y) and the consensus Revenue Es...
03-26 05:35
